Seven oncology drugs sit on the Food and Drug Administration's shortage list. One of them is ifosfamide, used against bone and soft tissue tumours and lymphoma, and short since a German manufacturer halted production after an FDA warning letter citing adulterated product — contamination and microbial growth.
That is the ordinary shape of a generic shortage, and this publication has described the economics before: the medicines that run short are the cheap old sterile injectables, because a clean room costs about the same whether the vial sells for eight cents or eighty dollars, and only one of those prices supports a spare line.
What is unusual here is the shape of the remedy. A company willing to make ifosfamide domestically faces a filing fee of nearly $360,000 to begin manufacturing the generic, and — the part that does not survive a second reading — may produce it only while the drug officially remains in shortage.
A permission that ends when it succeeds
Follow that through from the position of whoever has to sign the capital request. You spend the fee, you qualify a line, you hire and train the staff, you pass inspection. If you fail, you have lost the money. If you succeed, supply recovers, the drug comes off the shortage list, and the condition under which you were allowed to make it lapses.
The better your execution, the sooner your authorisation disappears. No competent finance function approves that.
The rule reads as though it were written to prevent something else entirely — opportunistic entry into a market during a temporary dislocation, presumably — and in isolation that is a reasonable thing to guard against. What it produces in combination with the fee is a structure in which the only rational entrant is one that expects the shortage to be permanent. Which is to say: the policy selects for suppliers who are betting against the problem being solved.
Meanwhile the shortage is not an abstraction on a list. A paediatric oncologist quoted in the reporting describes it changing treatment decisions, which is the only measure of a drug shortage that matters and the one that never appears in the filing.
This is the same failure this publication keeps finding wherever capacity meets a clock. The drydock is the constraint and it is booked years out because dock capacity answers a decade and not a cycle. A hospital runs on a supply chain with one of everything because a second source is a cost in every year but the one that matters. In each case the asset takes years to build and the demand signal lasts months, so nobody builds, and the shortage that follows is treated as a surprise rather than as the arithmetic it is.
The fix here is narrower than the pattern. A fee waiver for domestic production of drugs on the shortage list has been proposed by the company that would use it, which is worth noting as a declared interest rather than a disqualification. The condition is the more consequential half and costs nothing to change: authorise production for a fixed term rather than for the duration of the shortage, so that a manufacturer who fixes the problem is still permitted to keep making the thing that fixed it.
Until then the rule stands as written, and it says that the reward for ending a shortage is losing the right to supply the drug.
The count of oncology drugs on the FDA shortage list, the shortage of ifosfamide, the German manufacturer's halt following an FDA warning letter citing adulterated product, the filing fee of nearly $360,000 and the condition limiting production to the period of official shortage are as reported by WJLA's I-Team on 31 August 2026, which attributes the fee and the condition to Dr Alex Oshmyansky of Cost Plus Drugs and quotes Dr Pinki Prasad, a paediatric oncologist. The analysis is our own.
Topics healthmanufacturingregulation
